Results 251 to 260 of about 15,238,642 (306)

Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy. [PDF]

Kidney Med
Shivaraj K, Mamlouk O, Tchakarov A, Patel K, Abudayyeh A.   +4 more
europepmc   +1 more source

A strategic approach to managing Immune Effector Cell-Associated Hematotoxicity (ICAHT) during chimeric antigen receptor T-cell therapy. [PDF]

Blood Res
Yoon SE.
europepmc   +1 more source

Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. [PDF]

World J Clin Oncol
Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F.   +4 more
europepmc   +1 more source

Breakthroughs of chimeric antigen receptor T-cell therapy in hematological malignancies: From <i>ex vivo</i> to <i>in vivo</i>. [PDF]

Chin J Cancer Res
Pei X, Du Y, Lyu M, Huang X.
europepmc   +1 more source

Microfluidic perspectives on chimeric antigen receptor T-cell migration in solid tumours: highlighting physical confinement as a key barrier.

Mol Syst Des Eng
Gonzalez Abrego V, Chin MHW, Coppens MO.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Advances in chimeric antigen receptor T cells

Current Opinion in Hematology, 2020
Purpose of review To discuss the important advances in CAR T cell therapy over the past year, focusing on clinical results where available. Recent findings Approximately 30 years after they were first conceived of and 15 years after the first small-scale single-center clinical ...
Ofrat, Beyar-Katz, Saar, Gill
openaire   +2 more sources

Chimeric antigen receptor T cells march into T cell malignancies

Journal of Cancer Research and Clinical Oncology, 2023
T cell malignancies represent a diverse collection of leukemia/lymphoma conditions in humans arising from aberrant T cells. Such malignancies are often associated with poor clinical prognoses, cancer relapse, as well as progressive resistance to anti-cancer treatments.
Jie, Tang, Xudong, Zhao
openaire   +2 more sources

Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas

Hematology/Oncology Clinics of North America, 2023
The authors review the current use of chimeric antigen receptor (CAR)-transduced T cells (CAR-T) in Hodgkin lymphoma (HL) and T-cell lymphomas (TCL) and discuss the data on CD30-targeting CAR-T cells, which seem to be safe and effective in HL. In addition, the authors examine the use of CAR-T cells targeting CD30, CD5, or CD7 in TCL, while highlighting
Muhsen, Ibrahim N, Hill, LaQuisa C, Ramos, Carlos A   +2 more
openaire   +3 more sources

Chimeric antigen receptor T-cell toxicity

Current Opinion in Pediatrics, 2019
Purpose of review Chimeric antigen receptor -(CAR) T-cell therapy has become a commonly used immunotherapy originally used in the treatment of B-cell leukemias but which are now applied broadly across tumor classes. Although high rates of remission are associated with CAR T-cell therapy, toxicities associated with these novel ...
DaMarcus E, Baymon, Edward W, Boyer
openaire   +2 more sources